MML Investors Services LLC Grows Stock Position in Sanofi (NASDAQ:SNY)

MML Investors Services LLC increased its holdings in Sanofi (NASDAQ:SNY) by 4.7% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 241,401 shares of the company’s stock after acquiring an additional 10,865 shares during the period. MML Investors Services LLC’s holdings in Sanofi were worth $11,643,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Abel Hall LLC grew its holdings in shares of Sanofi by 1.8% in the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after purchasing an additional 194 shares in the last quarter. Providence Capital Advisors LLC grew its stake in shares of Sanofi by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company’s stock worth $2,653,000 after acquiring an additional 201 shares in the last quarter. Keudell Morrison Wealth Management increased its position in shares of Sanofi by 1.7% during the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock worth $624,000 after acquiring an additional 217 shares during the period. Bailard Inc. raised its stake in shares of Sanofi by 1.4% in the fourth quarter. Bailard Inc. now owns 16,359 shares of the company’s stock valued at $789,000 after acquiring an additional 220 shares in the last quarter. Finally, Old Port Advisors boosted its holdings in Sanofi by 0.6% in the fourth quarter. Old Port Advisors now owns 36,704 shares of the company’s stock valued at $1,770,000 after purchasing an additional 232 shares during the period. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. The Goldman Sachs Group began coverage on shares of Sanofi in a research report on Friday, March 21st. They set a “neutral” rating and a $65.00 price objective for the company. Finally, BNP Paribas assumed coverage on Sanofi in a report on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 target price on the stock. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $63.33.

Sanofi Trading Up 1.8 %

NASDAQ:SNY opened at $51.85 on Wednesday. The stock has a market capitalization of $130.99 billion, a price-to-earnings ratio of 20.82, a PEG ratio of 1.01 and a beta of 0.57. Sanofi has a 1 year low of $45.80 and a 1 year high of $60.12. The stock has a fifty day moving average price of $54.61 and a two-hundred day moving average price of $52.11. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, sell-side analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be issued a $2.0369 dividend. This represents a dividend yield of 3.1%. This is a boost from Sanofi’s previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. Sanofi’s payout ratio is 64.26%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.